Form 4: Sage Therapeutics Director Jessica Federer Granted 21,500 Stock Options

Jessica Federer, a Director at Sage Therapeutics, Inc., was granted 21,500 stock options with an exercise price of $6.77, vesting by June 2026.

Summary

• Jessica Federer, a Director of Sage Therapeutics, Inc. (SAGE), was granted 21,500 stock options.
• The options have an exercise price of $6.77 per share.
• The grant date for these options was June 11, 2025.
• The options were issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan, specifically as part of the Non-Employee Director Compensation Program.
• The options will vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, contingent on her continued service as a director.
• The expiration date for these options is June 11, 2035.
• Following this transaction, Jessica Federer beneficially owns 21,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a standard, expected compensation event for a director, which is generally positive for corporate governance as it aligns director incentives with shareholder interests. There are no negative surprises or red flags.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value, as the options gain value if the stock price increases.
• The issuance is part of a pre-existing, disclosed compensation program (2024 Equity Incentive Plan, Non-Employee Director Compensation Program), indicating standard corporate governance practices.

Risks

• The value of the stock options is subject to the future performance of Sage Therapeutics' common stock, meaning the options could become worthless if the stock price falls below the exercise price.
• Vesting is contingent on continued service as a director, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The document indicates a future vesting event for the granted stock options, contingent on continued service as a director until June 11, 2026, or the day prior to the 2026 Annual Meeting of Stockholders.

Industry Context

This Form 4 filing represents a routine compensation event for a director in the biotechnology/pharmaceutical industry. Equity-based compensation, such as stock options, is a common practice to align the interests of directors and executives with shareholders, encouraging long-term value creation in a sector often characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The granting of stock options to non-employee directors is a standard compensation practice across the biotechnology and broader corporate landscape.
• The specific exercise price of $6.77 and the number of options (21,500) would typically be benchmarked against peer companies of similar market capitalization and stage of development within the pharmaceutical industry, such as Biogen Inc., Vertex Pharmaceuticals Incorporated, or Alnylam Pharmaceuticals, Inc., to ensure competitive and appropriate director remuneration.
• Without specific peer compensation data, a direct quantitative comparison is not possible from this document alone, but the mechanism itself is consistent with industry norms.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing long-term stock price appreciation.
• Employees: No direct impact on employees mentioned, but the existence of an equity incentive plan suggests a broader framework for employee compensation as well.

Next Steps

• Continued service of Jessica Federer as a director until the vesting date (earlier of June 11, 2026, or the day prior to the 2026 Annual Meeting of Stockholders).
• Potential exercise of stock options by Jessica Federer on or after the vesting date and before the expiration date of June 11, 2035.

Key Dates

Recommendation

Keywords

Sage Therapeutics, SAGE, Stock Option, Equity Incentive Plan, Director Compensation, SEC Form 4, Insider Transaction, Jessica Federer, Biotechnology, Pharmaceuticals